Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder November 16, 2026 | 8:00 AM EST Webcast Add to Outlook Add to Google Calendar